Inhalation Drug Delivery Resources

  1. New Technologies To Improve Solubility Of Brick Dust Compounds 7/13/2022

    David Lyon, Ph.D., and Molly Adam answer attendee questions from a recent webinar about three enabling technologies designed to improve drug solubility in organic solvents for spray drying.

  2. Spray Drying To Enable New Inhaled Drug Products 7/11/2023

    The formulation and spray drying process can help manufacture a stable, highly respirable powder and deliver products that require a high drug load, a biologic, or rapid onset therapeutic.

  3. Six Inhaler Sustainability Myths – And Why They Must Be Busted 3/9/2022

    The solution to the carbon footprint of respiratory disease is complicated. The prevailing “myths” must be examined and addressed to achieve the shared industry vision of a decarbonized inhaler market.

  4. Emerging Trends And Opportunities In Orally Inhaled Drug Products 3/8/2024

    From targeting niche diseases to delivering cutting-edge medications, inhaled therapies are poised to become a cornerstone of modern medicine. Explore the intricacies of inhaled drug delivery.

  5. Contract Design And Development Vs. In-House: How To Find The Best Fit 3/21/2024

    Explore the rationale behind opting for a contract development organization (CDO) to fulfill organizational requirements and underscore vital considerations for evaluating CDOs to ensure alignment with your project objectives.

  6. Nasal Vaccine Development, Manufacturing, And Device Selection 7/11/2023

    When developing a nasal delivery program, a partner with experience in development and manufacturing techniques who can see a program through small-scale clinical to commercial supply is crucial.

  7. Driving Sustainability In Spray Drying Through Enabling Technologies

    By transitioning to alternative solvents or leveraging process aids, the challenges associated with the use of these chemicals can be addressed, helping create a sustainable, greener footprint.

  8. Combination Products: Market Trends And Regulatory Considerations 1/17/2024

    Combination products provide significant avenues for increasing patient adherence and overall efficacy. This collection outlines the opportunity and identifies strategies for gaining regulatory approval.

  9. Streamlining The Path To Market For Generic Drug-Device Combinations 9/18/2024

    Developing g-DDCPs is a complex and time-consuming process. By using a risk-based approach, manufacturers can streamline the development process and bring g-DDCPs to market more quickly.

  10. Using 505(B)(2) To Streamline Approval Of Combination Products 2/2/2023

    In recent years, the quantity of approvals for products and 505(b)(2) applications has risen, causing developers to map out their regulatory strategy as early as possible.